Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors

NCT05229601 is registered in ClinicalTrials.gov with HiFiBiO Therapeutics as lead sponsor.

NCT NCT05229601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05229601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors
Lead sponsor
HiFiBiO Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
April 20, 2022
Completion date
May 30, 2024
Enrollment
31 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, renal cell carcinoma, soft tissue sarcoma, uterine carcinosarcoma